TY - JOUR
T1 - Breast cancer survival in Nordic BRCA2 mutation carriers—unconventional association with oestrogen receptor status
AU - Olafsdottir, Elinborg J.
AU - Borg, Ake
AU - Jensen, Maj Britt
AU - Gerdes, Anne Marie
AU - Johansson, Anna L.V.
AU - Barkardottir, Rosa B
AU - Johannsson, Oskar T.
AU - Ejlertsen, Bent
AU - Sønderstrup, Ida Marie Heeholm
AU - Hovig, Eivind
AU - Lænkholm, Anne Vibeke
AU - Hansen, Thomas van Overeem
AU - Olafsdottir, Gudridur H.
AU - Rossing, Maria
AU - Jonasson, Jon G.
AU - Sigurdsson, Stefan
AU - Loman, Niklas
AU - Nilsson, Martin P.
AU - Narod, Steven A.
AU - Tryggvadottir, Laufey
PY - 2020/11/24
Y1 - 2020/11/24
N2 - Background: The natural history of breast cancer among BRCA2 carriers has not been clearly established. In a previous study from Iceland, positive ER status was a negative prognostic factor. We sought to identify factors that predicted survival after invasive breast cancer in an expanded cohort of BRCA2 carriers. Methods: We studied 608 women with invasive breast cancer and a pathogenic BRCA2 mutation (variant) from four Nordic countries. Information on prognostic factors and treatment was retrieved from health records and by analysis of archived tissue specimens. Hazard ratios (HR) were estimated for breast cancer-specific survival using Cox regression. Results: About 77% of cancers were ER-positive, with the highest proportion (83%) in patients under 40 years. ER-positive breast cancers were more likely to be node-positive (59%) than ER-negative cancers (34%) (P < 0.001). The survival analysis included 584 patients. Positive ER status was protective in the first 5 years from diagnosis (multivariate HR = 0.49; 95% CI 0.26–0.93, P = 0.03); thereafter, the effect was adverse (HR = 1.91; 95% CI 1.07–3.39, P = 0.03). The adverse effect of positive ER status was limited to women who did not undergo endocrine treatment (HR = 2.36; 95% CI 1.26–4.44, P = 0.01) and patients with intact ovaries (HR = 1.99; 95% CI 1.11–3.59, P = 0.02). Conclusions: The adverse effect of a positive ER status in BRCA2 carriers with breast cancer may be contingent on exposure to ovarian hormones.
AB - Background: The natural history of breast cancer among BRCA2 carriers has not been clearly established. In a previous study from Iceland, positive ER status was a negative prognostic factor. We sought to identify factors that predicted survival after invasive breast cancer in an expanded cohort of BRCA2 carriers. Methods: We studied 608 women with invasive breast cancer and a pathogenic BRCA2 mutation (variant) from four Nordic countries. Information on prognostic factors and treatment was retrieved from health records and by analysis of archived tissue specimens. Hazard ratios (HR) were estimated for breast cancer-specific survival using Cox regression. Results: About 77% of cancers were ER-positive, with the highest proportion (83%) in patients under 40 years. ER-positive breast cancers were more likely to be node-positive (59%) than ER-negative cancers (34%) (P < 0.001). The survival analysis included 584 patients. Positive ER status was protective in the first 5 years from diagnosis (multivariate HR = 0.49; 95% CI 0.26–0.93, P = 0.03); thereafter, the effect was adverse (HR = 1.91; 95% CI 1.07–3.39, P = 0.03). The adverse effect of positive ER status was limited to women who did not undergo endocrine treatment (HR = 2.36; 95% CI 1.26–4.44, P = 0.01) and patients with intact ovaries (HR = 1.99; 95% CI 1.11–3.59, P = 0.02). Conclusions: The adverse effect of a positive ER status in BRCA2 carriers with breast cancer may be contingent on exposure to ovarian hormones.
U2 - 10.1038/s41416-020-01056-4
DO - 10.1038/s41416-020-01056-4
M3 - Article
C2 - 32939053
AN - SCOPUS:85091156088
SN - 0007-0920
VL - 123
SP - 1608
EP - 1615
JO - British Journal of Cancer
JF - British Journal of Cancer
IS - 11
ER -
